Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922490 · ClinicalTrials.gov registry record · Phase 4
Lipogems Prospective Study
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03922490 is a Phase 4 study that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 2 participants.
The verdict
NCT03922490, a Phase 4 study, was terminated before completion, sponsored by Hospital for Special Surgery, New York.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to study the clinical outcomes and effects of the injection of fat-derived stem cells (the scientific name being "adipose derived autologous stem cell transplantation (ADAT)") as an addition to knee arthroscopy in the treatment of knee swelling and pain associated with mild to moderate knee osteoarthritis. Management of this condition remains a pervasive problem within orthopaedics. Lipogems is a Food and Drug Administration (FDA) approved technique. Lipogems is the name of the technology used to obtain stem cells from fat that will be aspirated/removed by suction from the abdomen. Fat will be processed to obtain stem cells which will then be injected into the knee after the physician completes knee arthroscopy. The study that we are asking patients to enroll in is important because it will attempt to answer the question about whether fat-derived stem cells added to knee arthroscopy is better, worse or no different than knee arthroscopy alone. Currently, without this study, we do not have an answer to this question.
Interventions
- DEVICE Lipogems Device PLUS debridement
- PROCEDURE Debridement only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-11-11 |
| Est. Completion | 2020-02-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922490
The ClinicalTrials.gov registry entry for NCT03922490 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lipogems Device PLUS debridement is the first listed.
NCT03922490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03922490 about?
NCT03922490 is a clinical study titled "Lipogems Prospective Study". The purpose of this study is to study the clinical outcomes and effects of the injection of fat-derived stem cells (the scientific name being "adipose derived autologous stem cell transplantation (ADAT)") as an addition to knee arthroscopy in the treatment of knee swelling and pain associated with m...
What is the current status of trial NCT03922490?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2019-11-11. Estimated completion is 2020-02-27.
What interventions are being tested in trial NCT03922490?
The interventions under investigation include: Lipogems Device PLUS debridement (DEVICE), Debridement only (PROCEDURE).
Who is sponsoring clinical trial NCT03922490?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.